Active, not recruitingPhase 4NCT06635057
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
Studying MODY
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- Tirzepatide(drug)
- Enrollment
- 130 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (29)
- Al Moosa Specialist Hospital, Al Ahasa, Saudi Arabia
- National Guard Hospital-King Abdulaziz Medical City, Alahsa, Saudi Arabia
- King Abdulaziz Medical City-Jeddah, Jeddah, Saudi Arabia
- King Fahad Armed Forces Hospital Jeddah, Jeddah, Saudi Arabia
- King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia
- Saudi Airlines Medical services, Jeddah, Saudi Arabia
- King Faisal Specialist Hospital and Research Center Madina, Madinah, Saudi Arabia
- King Saud University, Riyadh, Saudi Arabia
- Osepdale Fatebenefratelli e Oftalmico, Riyadh, Saudi Arabia
- Al Dallah Hospital, Riyadh, Saudi Arabia
- Sulaiman Habib Olaya, Riyadh, Saudi Arabia
- Specialized Medical Center Hospital, Riyadh, Saudi Arabia
- Dallah Namar Hospital, Riyadh, Saudi Arabia
- Dr. Sulaiman Al Habib Hospital As Suwaidi, Riyadh, Saudi Arabia
- Dr. Sulaiman Al Habib Medical Complex Arrayan Saudi Arabia, Riyadh, Saudi Arabia
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06635057 on ClinicalTrials.govOther trials for MODY
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07452887Education and Mobile Reminder Program for Foot Self-Care in Type 2 DiabetesSelma Sahin
- RECRUITINGNANCT07195994A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 DiabetesQuickSilver Scientific
- ACTIVE NOT RECRUITINGNANCT07530575Limosilactobacillus Fermentum CRL 1446 - CONICET CASASCOPINER Pastor Manfredi Winery
- ACTIVE NOT RECRUITINGPHASE1NCT07137585A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityHoffmann-La Roche
- RECRUITINGPHASE4NCT07112339A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesNovo Nordisk A/S
- RECRUITINGEARLY PHASE1NCT06609356Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 DiabetesVanderbilt University Medical Center
- RECRUITINGNANCT06118931Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic ControlUniversity of Toronto
- RECRUITINGNANCT06942195Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 DiabetesUniversity of Adelaide